- Home
- CRVS vs GPRE Comparison
CRVS vs GPRE Comparison
Compare CRVS & GPRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- GPRE
- Stock Information
- Founded
- CRVS 2014
- GPRE 2004
- Country
- CRVS United States
- GPRE United States
- Employees
- CRVS 31
- GPRE N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- GPRE Major Chemicals
- Sector
- CRVS Health Care
- GPRE Industrials
- Exchange
- CRVS Nasdaq
- GPRE Nasdaq
- Market Cap
- CRVS 328.5M
- GPRE 289.7M
- IPO Year
- CRVS 2016
- GPRE N/A
- Fundamental
- Price
- CRVS $3.92
- GPRE $5.65
- Analyst Decision
- CRVS Strong Buy
- GPRE Buy
- Analyst Count
- CRVS 4
- GPRE 7
- Target Price
- CRVS $15.00
- GPRE $10.42
- AVG Volume (30 Days)
- CRVS 786.0K
- GPRE 1.8M
- Earning Date
- CRVS 08-05-2025
- GPRE 08-05-2025
- Dividend Yield
- CRVS N/A
- GPRE N/A
- EPS Growth
- CRVS N/A
- GPRE N/A
- EPS
- CRVS N/A
- GPRE N/A
- Revenue
- CRVS N/A
- GPRE $2,463,097,000.00
- Revenue This Year
- CRVS N/A
- GPRE $2.90
- Revenue Next Year
- CRVS N/A
- GPRE $1.54
- P/E Ratio
- CRVS N/A
- GPRE N/A
- Revenue Growth
- CRVS N/A
- GPRE N/A
- 52 Week Low
- CRVS $1.75
- GPRE $3.14
- 52 Week High
- CRVS $10.00
- GPRE $18.14
- Technical
- Relative Strength Index (RSI)
- CRVS 49.54
- GPRE 71.89
- Support Level
- CRVS $3.83
- GPRE $4.44
- Resistance Level
- CRVS $4.33
- GPRE $5.95
- Average True Range (ATR)
- CRVS 0.28
- GPRE 0.34
- MACD
- CRVS -0.03
- GPRE 0.16
- Stochastic Oscillator
- CRVS 21.74
- GPRE 88.50
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About GPRE Green Plains Inc.
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.